Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Alnylam Pharmaceuticals, Inc. $805 Million Common Stock Offering
Davis Polk advised the underwriters of an $805 million SEC-registered offering of 6,440,000 shares of common stock of…
Davis Polk Advises Roche on Its €250 Million Cash Tender Offer
Davis Polk advised Roche Holdings, Inc. as to U.S. law in connection with its cash tender offer for up to €250 million…
Davis Polk Advises InflaRx N.V. on Its Initial Public Offering
Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition,…
Insulet Corporation Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $402.5…
Celgene $3 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $750 million…
Davis Polk Advises McKesson Corporation on Its Acquisition of RxCrossroads from CVS Health Corporation
Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to…
Allena Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of…
Omnicell, Inc. $125 Million SEC-Registered At-The-Market Offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Omnicell, Inc. of…
Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ
Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230…
Advanced Accelerator Applications $3.9 billion acquisition by Novartis
Davis Polk is advising Advanced Accelerator Applications S.A. on its $3.9 billion acquisition by Novartis. Entry into…